UK SACT BOARD

October 2026

To: Chief Executives, Medical Directors and SACT Leads, NHS Trusts and Health Boards across the United Kingdom

Subject: Governance Considerations for the Use of Electronic Consent (e-Consent) in Systemic Anti-Cancer Therapy

Dear Colleagues,

A library of national standardised SACT regimen-specific consent forms is hosted on the Cancer Research UK (CRUK) website and endorsed by the UK SACT Board.

Commercial digital e-consent platforms are becoming established within UK healthcare organisations for various treatments and procedures. Some trusts are exploring their application for consenting patients undergoing Systemic Anti-Cancer Therapy (SACT).

While the potential benefits of digital consent platforms, such as improved accessibility, electronic documentation and patient experience are recognised, the UK SACT Board currently only endorses the SACT Regimen-Specific Consent Forms hosted on the CRUK website. These forms are governed by an expert project Steering Committee, which maintains a rigorous, national governed process covering more than 500 regimens. This ensures all content remains accurate, aligned with current Summary of Product Characteristics (SmPC), is robustly version-controlled, and responsive to urgent safety updates or clinical changes.

At present, we are not aware of any e-consent provider that has established a centralised governance framework capable of ensuring that digital forms remain consistently accurate, version-controlled, and responsive to urgent safety updates. Consequently, these commercial digital forms may not mirror national standards and are not endorsed by the UK SACT Board.

Providers are advised to continue using the nationally governed SACT Regimen-Specific Consent Forms hosted on the CRUK website for SACT consent. Organisations choosing to use digital solutions should refer to the official 'Guidance on Electronic Consent' available via the CRUK Regimen-Specific Consent Forms website, noting the clear disclaimers within the guidance. Where organisations choose to implement a commercial e-consent platform, they must undertake a comprehensive local risk assessment and establish robust local governance to manage clinical safety, content accuracy and version control.

We would also like to assure colleagues that the National project Steering Committee is actively exploring how central governance structures could be developed to support the safe implementation of e-consent solutions across multiple providers. This work is ongoing, and we will provide further updates as national recommendations evolve.

The UK SACT Board remains committed to supporting safe, high-quality and patient-centred consent processes across the UK and would encourage organisations to carefully consider the governance implications of any proposed e-consent implementation.

Yours sincerely,

On behalf of the UK SACT Board

Ruth Hammond - Chair, UK SACT Board

Rosie Roberts - Deputy Chair UK SACT Board